GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Channel Therapeutics Corp (AMEX:CHRO) » Definitions » Price-to-Owner-Earnings

CHRO (Channel Therapeutics) Price-to-Owner-Earnings : (As of Apr. 30, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Channel Therapeutics Price-to-Owner-Earnings?

As of today (2025-04-30), Channel Therapeutics's share price is $1.1884. Channel Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Channel Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:


CHRO's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.2
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2025-04-30), Channel Therapeutics's share price is $1.1884. Channel Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.47. Therefore, Channel Therapeutics's PE Ratio (TTM) for today is At Loss.

As of today (2025-04-30), Channel Therapeutics's share price is $1.1884. Channel Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-1.53. Therefore, Channel Therapeutics's PE Ratio without NRI for today is At Loss.


Channel Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Channel Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Channel Therapeutics Price-to-Owner-Earnings Chart

Channel Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Owner-Earnings
- - - - -

Channel Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Channel Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Channel Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Channel Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Channel Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Channel Therapeutics's Price-to-Owner-Earnings falls into.


;
;

Channel Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Channel Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1.1884/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Channel Therapeutics  (AMEX:CHRO) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Channel Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Channel Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Channel Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
4400 Route 9 South, Suite 1000, Freehold, NJ, USA, 07728
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.